5 reasons to avoid Slater & Gordon Limited shares

Slater & Gordon Limited's (ASX:SGH) share price has fallen more than 95% over the last 11 months.

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

What was one of the most successful shares on the Australian share market between 2007 and early 2015 has become the battering ram of investors over the last 11 months or so.

From a high of $8.07 in April 2015, the share price of listed law firm Slater & Gordon Limited (ASX: SGH) has collapsed more than 95% to just 39 cents today, although it did trade as low as 22.7 cents last week. The shares have gained 6.9% today.

Indeed, seeing what was a multi-billion dollar corporation less than a year ago worth just over $137 million today is sure to raise the interest of some investors looking to make good on a potential rebound. Of course, a rebound could be on the cards, but those investors who buy could just as easily be trying to catch a falling knife.

Here are five reasons why I think it would be wise to avoid buying shares of Slater & Gordon just yet…

  1. Management. When you board a plane, you ought to have the utmost confidence in the pilot that he/she is trustworthy and can get you to your destination safely. It's the same when investing in shares of any business. Unfortunately, Slater & Gordon's management team have lost the trust of investors after repeatedly reiterating previous guidance calls (only to alter them days or weeks later), while both Slater & Gordon and its new Quindell business have also been under investigation by market regulators. That's a clear reason to steer clear.
  2. Impairments. Slater & Gordon paid $1.2 billion for Quindell's Professional Services division last year, raising nearly $900 million in additional capital from shareholders in the process. At its most recent half-year results, it booked an $814.2 million impairment on the business (now called Slater & Gordon Solutions, or SGS), as well as another $62 million impairment on other assets. That's a huge waste of shareholder capital.
  3. United Kingdom. Bad turned to terrible for Slater & Gordon when proposed changes were made to personal injury laws in the United Kingdom – the market Slater & Gordon had just paid $1.2 billion to expand into. Basically, the proposed changes would impact compensation claims surrounding minor motor accident injuries, effectively reducing the need for lawyers. Slater & Gordon really lucked out on that one.
  4. Debt. Slater & Gordon has built its business around acquisitions, and it's accumulated a huge pile of debt in the process. With just $51.9 million of cash and cash equivalents as at 31 December 2015, it had more than $790 million in short and long-term debt.
  5. Financing Arrangements. To make matters worse, Slater & Gordon's creditors could soon be knocking on the door demanding repayment. The company will meet with its banking syndicate, made up of National Australia Bank Ltd. (ASX: NAB) and Westpac Banking Corp (ASX: WBC), in the coming weeks to propose a plan to repay its debts and, if the banks aren't happy with the arrangement, they could force Slater & Gordon to repay what it owes by 31 March, 2017.

Investors are often told of the benefits of buying shares when they've fallen in price. That applies to high-quality businesses that may be experiencing short-term struggles, or when the market is simply selling down their shares.

But in Slater & Gordon's situation, it seems there are a multitude of reasons why investors have lost confidence in the business, and justifiably so. Slater & Gordon's shares could rise over the coming years – perhaps considerably – but they're also very risky and that's why I think it would be wise to steer clear.

Motley Fool contributor Ryan Newman has no position in any stocks mentioned. Unless otherwise noted, the author does not have a position in any stocks mentioned by the author in the comments below. You can follow Ryan on Twitter @ASXvalueinvest. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »